Samil Pharm signs deal for commercialization of Aramchol

- All
- Industry
- Technology
- Mobility
- Economy
- Market
- All
- Culture
- Travel
- Food
- Books
- People
- Arts & Design
- Film
- Television
- Performance
- All
- Soccer
- Baseball
- Golf
- More Sports

Link copied

22:04
Top prosecutor orders speedy investigation into first lady's alleged acceptance of luxury handbag
20:24
Lawmakers express woes over Japan's actions against Naver
20:07
Medical students file appeal after court denial of injunction to halt quota hike
19:52
Army takes group action against Hybe for neglecting BTS
19:38
Hankook Tire takes over control of Hanon Systems
19:38
S. Korea, Japan, China agree to create new financing facility against regional crises
19:13
Woori to re-enter brokerage business with acquisition of Korea Foss Securities
19:11
[From the Scene] Uzbekistan pursues economic reforms to attract foreign investment
18:18
Naver will consider company benefits in deciding on selling Line shares: CEO
18:10
East German commissioner calls on S. Korea to seize unexpected opportunities for unification

Samil Pharm signs deal for commercialization of Aramchol

July 29, 2016 - 14:02 By 윤정현

[DISCLOSURE] Samil Pharmaceutical (000520) announced on July 29 that it has signed a license agreement with Galmed Pharmaceuticals for the commercialization of Aramchol for the treatment of fatty liver indications including Non-Alcoholic Steato-hepatitis (NASH) in Korea.
Samil will pay Galmed a fee of US$8.08 million for the deal.

윤정현

daum

Most Popular